New anticoagulants paved the way for a new indication in secondary prevention after an acute coronary syndrome. First results have shown a significant reduction of cardiovascular events, yet an increased hemorrhagic risk. On the other hand, the use of new antiplatelet therapies in patients with acute coronary syndrome increases the cases where an additional new oral anticoagulant is required. The first studies on this association have revealed an increased risk of bleeding. However, numerous studies assessing the efficacy and risk of this association are ongoing.
What is already known about the topic?
The advent of new anticoagulants in patients with acute coronary syndrome rose questions about their indications and use.
What does this article bring up for us?
This article reviews the current knowledge on the use of anticoagulants and antiplatelet agents in patients with atrial fibrillation and acute coronary syndrome
Key Words
Anticoagulant, antiplatelet agent, acute coronary syndrome